Physician profile
Thomas Rennie
NPI 1265423982
$113,212.39
in general payments reported to CMS, 2019-2025
36 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,219 · 2020: $11K · 2021: $26K · 2022: $14K · 2023: $15K · 2024: $15K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Honoraria: $11K · Food and Beverage: $10K · Travel and Lodging: $2,040 · Education: $10.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,050.00 |
| Honoraria | $10,800.00 |
| Food and Beverage | $10,215.61 |
| Travel and Lodging | $2,039.96 |
| Education | $10.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36,280.52 | 2019-2025 | Krystexxa, Enbrel, Otezla |
| Horizon Therapeutics Plc | $34,192.26 | 2019-2023 | Krystexxa |
| Pacira Therapeutics, INC. | $28,646.00 | 2019-2021 | |
| Glaxosmithkline, LLC. | $1,828.85 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $1,641.84 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,572.54 | 2019-2025 | |
| Janssen Biotech, INC. | $1,169.42 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,147.77 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,125.78 | 2020-2025 | Acthar |
| Genentech USA, INC. | $924.23 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Lilly USA, LLC | $646.08 | 2019-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $595.91 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $550.61 | 2019-2025 | |
| Abbvie INC. | $519.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.46 | 2021-2025 | Saphnelo |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rennie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.